Skip to main content

Table 2 Patient characteristics

From: Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

 

Patients (N = 216) in NEOZOTAC

Median age, years (range)

 

49.5 (28–70)

Median BMI, kg/m2 (range)

 

26.2 (18.3–42.0)

Clinical T stage

cT1 or cT2

123 (56.9 %)

 

cT3 or cT4

93 (43.1 %)

Clinical N stage

cN0

101 (46.8 %)

 

cN+

115 (53.2 %)

Tumor type

Ductal

128 (59.3 %)

 

Lobular

38 (17.6 %)

 

Other

18 (8.4 %)

 

Unknown

32 (14.8 %)

HR status

ER+ and/or PR+

180 (83.3 %)

 

ER– and PR–

36 (16.7 %)

Allocated treatment

TAC

109 (50.5 %)

 

TAC + ZA

107 (49.5 %)

pCR breast and LN

Yes

25 (11.6 %)

 

No

184 (85.2 %)

 

Unknown

7 (3.2 %)

MP breast

1

33 (15.3 %)

 

2

56 (25.9 %)

 

3

41 (19.0 %)

 

4

42 (19.4 %)

 

5

35 (16.2 %)

 

Unknown

9 (4.2 %)

  1. BMI body mass index, ER estrogen receptor, HR hormone receptor, LN lymph nodes, MP Miller and Payne, pCR pathologic complete response, PR progesterone receptor, TAC docetaxel, doxorubicin, and cyclophosphamide, ZA zoledronic acid